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The Journal of Immunology Gender Differences in 1,25 Dihydroxyvitamin D 3 Immunomodulatory Effects in Multiple Sclerosis Patients and Healthy Subjects Jorge Correale, María C. Ysrraelit, and María I. Gaitán Vitamin D 3 is best known as a calcium homeostasis modulator; however, it also has immune-modulating potential. In this study, we demonstrated that immunomodulatory effects of vitamin D 3 are significantly stronger in females than in males in multiple sclerosis patients, as well as in healthy subjects. Inhibition of self-reactive T cell proliferation and reduction in IFN-g-and IL-17-secreting cell numbers were considerably greater in females. Furthermore, the increase in IL-10-secreting and CD4 + CD25 + FoxP3 + regulatory T cell numbers were also greater in females. In parallel with these findings, female subjects had fewer 
M ultiple sclerosis (MS)
is an inflammatory demyelinating disease affecting the CNS, in which autoimmunemediated mechanisms induce myelin injury (1) . It is generally accepted that autoimmune diseases, such as MS, arise from a complex interaction between genetic susceptibility and environmental factors (2, 3) . The genetic component of MS is thought to result from the action of common allelic variants in several genes (4) . However, discordance of MS development between monozygotic twins suggests that additional factors could be involved (5) . Geographical differences in disease incidence and prevalence, as well as studies of populations migrating from areas of low risk to areas of high risk, strongly support a role for environmental factors in disease pathogenesis (6, 7) . Vitamin D 3 is best known as a calcium homeostasis modulator; however, experimental and clinical observations provide evidence that vitamin D 3 is also an environmental factor exerting significant influence over immunoregulation, ultimately affecting MS prevalence. A protective effect was proposed after observations indicating reduced risk for disease development associated with sunlight exposure and use of vitamin D 3 supplements (8) (9) (10) (11) (12) (13) (14) (15) . A recent longitudinal study conducted among American patients showed decreased MS risk in white patients with increased 25-hydroxyvitamin D 3 [25-(OH)D 3 ] serum levels, and a greater degree of disability has been strongly associated with lower 25-(OH)D 3 levels and reduced sun exposure (16) . Moreover, a recent genome-wide association study conducted by the Australian and New Zealand gene consortium identified new MS risk associated with single nucleotide polymorphisms on chromosome 12q13-14 near the gene CYP27B1, encoding the enzyme that converts inactive 25-(OH)D 3 into 1,25-dihydroxyvitamin D 3 [1, 2 D 3 ], the biologically active metabolite of vitamin D 3 (17) . These findings converge with experimental evidence indicating a protective effect for vitamin D 3 in animal models of MS. For example, experimental autoimmune encephalomyelitis (EAE) can be prevented by administering the active metabolite 1,25-(OH) 2 D 3 prior to immunization and ameliorated when given after disease onset (18, 19) . Conversely, vitamin D 3 deficiency decreased the time to EAE onset and increased disease severity (19, 20) . Interestingly, recent investigations showed that 1,25-(OH) 2 D 3 significantly inhibits EAE in female mice, but not in male mice, and that ovariectomy abrogates this protective effect, suggesting a link between female sex hormones and 1,25-(OH) 2 D 3 metabolism (21) . Synergy between 17-b estradiol (E2) and 1,25-(OH) 2 D 3 occurred through 1,25-(OH) 2 D 3 -mediated enhancement of E2 synthesis, as well as E2-mediated enhancement of CNS vitamin D 3 receptor (VDR) transcription and function (22) . Given the evidence indicating that 1,25-(OH) 2 D 3 immune response modulation exists in vitro and in animal models, assessing whether this modulation might also be found in MS patients becomes a most interesting question.
Previously, we demonstrated that relapsing-remitting MS patients present reduced serum 25-(OH)D 3 levels and 1,25-(OH) 2 D 3 levels compared with healthy subjects, particularly during exacerbations; this suggests that 1,25-(OH) 2 D 3 -dependent T cell regDepartment of Neurology, Raúl Carrea Institute for Neurological Research, Buenos Aires, Argentina ulation may play an important role in maintaining T cell homeostasis in this group of patients (25) . In this study, we investigated the immunomodulatory effects of 1,25-(OH) 2 
Materials and Methods

Patients and control subjects
Ninety-two Hispanic patients with a diagnosis of relapsing-remitting MS, according to Poser's and McDonald's criteria (24, 25) , were studied: 34 during exacerbations and 58 in remission. Exacerbations were defined as development of new symptoms or worsening of pre-existing ones, confirmed on neurologic examination and lasting $48 h, in the absence of fever, and preceded by stability or improvement lasting $30 d. Patients with inflammatory, endocrine, or major psychiatric disorders were excluded from the study. Patients had not received steroids for $6 mo prior to study entry nor any other inmunomodulatory or immunosuppressive drugs or dietary supplements. All patients lived in the city of Buenos Aires (latitude 34˚S, longitude 58˚W). No postmenopausal women were included in the study. No differences in clinical disability or disease duration were observed between male and female patients included in this cohort. Thirty healthy individuals, matched for race/ethnicity, age, gender, and place of residence served as controls. Other underlying disorders were ruled out after thorough clinical and neurologic examination and standard chemical and hematological laboratory examinations. Control individuals were not taking any medication or dietary supplements. Samples from healthy controls were collected during the same months of the year as samples from MS patients. Demographic and clinical characteristics of patients and controls are shown in Table I . Blood samples were obtained from relapsing-remitting MS patients during remission for in vitro T cell function analysis in all cases. The study was approved by the Institutional Ethics Committee.
Determination of serum 25-(OH)D 3 and 1,25-(OH) 2 D 3 levels Serum 25-(OH)D 3 and 1,25-(OH) 2 D 3 levels were measured using commercially available ELISA kits (Immundiagnostik, Bensheim, Germany), following the manufacturer's instructions. Assay sensitivity levels were 10 ng/ml and 6.0 pg/ml, respectively. Intra-and interassay variation coefficients were ,7.5% and ,6.8%, respectively.
Ag preparation
Myelin basic protein (MBP) 83-102 (ENPVVHFFKNIVFPRTPPPS), MBP 143-168 (GVDAQGTLSKIFKLGGRDSRSGSPMA), and myelin oligodendrocyte glycoprotein (MOG) (PEYRGRTELLKDAIGEGKVTL-RIRN) peptides were synthesized with an automated peptide synthesizer using FAST-MOC chemistry (26) . Peptides were cleaved from resin using trifluoroacetic acid, chromatographed on Sephadex G-10 with 30% acetic acid, and lyophilized. Each peptide was analyzed by HPLC and was found to have the amino acid composition expected.
CD4
+ cell enrichment, generation of MBP and MOG peptidereactive T cell lines, and macrophage isolation PBMCs were isolated by Ficoll-Hypaque density-gradient centrifugation (Pharmacia, Peapack, NJ), and CD4 + T cells were positively selected using Dynabeads M-450 CD4 beads (Dynal Biotech, Oslo, Norway). Separation was monitored using flow-cytometry analysis, demonstrating .97% purity. MBP-and MOG-peptide specific T cell lines (TCLs) were expanded from peripheral blood, as previously described (27) . Briefly, 5 3 10 6 PBMCs were stimulated with optimal concentrations of MBP or MOG peptides (10-20 mg/ml). After 5-7 d, cells were recultured in fresh medium containing 50 U/ml human rIL-2 (R&D Systems, Minneapolis, MN) for an additional week. Restimulation cycles with autologous irradiated PBMCs (3000 rad) as APCs plus peptide, followed by expansion with rIL-2, were repeated weekly. After four cycles of restimulation and expansion, TCLs were evaluated using standard proliferation assays. Cut-off values for a positive response were set at stimulation index .3. All MBP-and MOG-reactive TCLs were .93% CD4 + .
For macrophages, isolation monocytes were positively selected from PBMCs using anti-CD14-coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany), following the manufacturer's instructions. (27) . Thymidine incorporation (cpm) was calculated as the mean value of triplicate cultures. 1,25-(OH) 2 D 3 was dissolved in absolute ethanol at a stock concentration of 0.01 M and further diluted in RPMI 1640 medium to the concentrations tested. Additional controls included viability studies using trypan blue dye exclusion, the addition of ethanol diluted to concentrations equivalent to those used for 1,25-(OH) 2 D 3 dilutions, and serum-free medium without phenol red. This last control was included to rule out possible estrogen-like activity of phenol red (28) . No autologous serum was used in any of the culture conditions.
Quantification of cytokines secreted
The number of CD4 + T cells or MBP-and MOG-peptide specific T cells secreting IL-10, IL-17, and IFN-g was evaluated using commercially available kits (R&D Systems) for single-cell resolution ELISPOT assays, following the manufacturer instructions, with and without 1,25-(OH) 2 
Real-time quantitative RT-PCR analysis
For quantitative assessment of relative mRNA levels, total RNA was prepared using TRIzol LS reagent (Invitrogen, Carlsbad, CA), following the manufacturer's instructions. RNA was reverse transcribed using an M-MLV RT reverse-transcription kit with random hexamer primers (Invitrogen). Relative levels of VDR, CYP27B1, and CYP24A1 transcripts were determined by real-time PCR (ABI 7000 sequence detection system; Applied Biosystems, Foster City, CA), using a SYBR green PCR mix. Values obtained were normalized to GAPDH transcripts as an internal control. These values were then standardized such that a minimum value of 1.0 was assigned to the group with the lowest gene expression. The following primer sequences were used: GAPDH: forward 59-GAAGGTGAAGTCGATGTCC-39; CYP27B1: forward 59-TTGGCAAGCGCAGCTGTAT-39, reverse 59-TGTGTTAGGATCTGGGCCAAA-39; and CYP24A1: forward 59-CAAACCGTGGAAGGCCTATC-39, reverse 59-AGTCTTCCCCTTCC-AGGATCA-39.
Measurement of circulating vitamin D-binding protein and vitamin D-binding protein uptake
Free circulating vitamin D-binding protein (DBP) levels were measured in serum from male and female MS patients using a commercially available kit for ELISA (Immundiagnostik), following the manufacturer's instructions. Assay sensitivity level was 1.23 ng/ml. Intra-and interassay variation coefficients were ,5% and ,11%, respectively.
Quantitation of DBP uptake was assessed, as described previously, but with some modifications (29, 30) . Briefly, DBP (Calbiochem, Darmstadt, Germany) was conjugated with FITC using a commercial kit (SigmaAldrich). The final FITC/protein molar ratio was 1:1. Prior to all experiments, cells were incubated for 30 min at 37˚C in RPMI 1640 serum-free medium (JRH Biosciences) to deplete them of endogenous proteins and proteins internalized from the culture medium. Cells (10 5 / tube) harvested at different times were incubated at 4˚C (to inhibit uptake) or 37˚C (optimal uptake temperature) in OVA/RPMI 1640 medium containing 2 mM FITC-DBP. Tubes were previously coated for 2 h at 37˚C with a solution of 1.5% OVA in PBS. After incubation, cells were washed in ice-cold PBS containing 5% FCS and 0.1% NaN 3 to stop internalization. Cells were then fixed with 4% paraformaldehyde in PBS, and samples were analyzed by FACScan using CellQuest software (BD Biosciences). Relative fluorescence intensity of $5000 cells per sample was recorded as single-parameter histograms, and the mean fluorescence intensity was calculated for each histogram as an indicator of the number of DBP molecules incorporated per cell at the different times and culture conditions specified.
Statistical analysis
Differences in 25-(OH)D 3 and 1,25-(OH) 2 D 3 levels between males and females were analyzed using the two-tailed Student t test. Differences in immunological variables were tested for significance using the MannWhitney U test. In all cases, p values ,0.05 were considered statistically significant.
Results
Female and male subjects showed similar serum levels of 25-(OH)D 3 and 1,25-(OH) 2 D 3 In a first approach to investigate whether gender differences existed in relation to immunological effects of vitamin D 3 , serum levels of 25-(OH)D 3 and 1,25-(OH) 2 D 3 were quantified in male and female MS patients, as well as in healthy controls (Table I) . As illustrated in Fig. 1 The impact of 1,25-(OH) 2 D 3 on T cell cytokine production of IFN-g, IL-17, and IL-10 was measured in males and females, using ELISPOT assays, in purified CD4 + T cells and in myelin peptide-specific TCLs stimulated with immobilized anti-CD3 mAb, in the presence and absence of 1,25-(OH) 2 D 3 . Fig. 3 demonstrates the significant differences observed between the genders in the secretion patterns of these three cytokines.
1,25-(OH) 2 D 3 reduced the number of IFN-g-and IL-17-producing cells significantly more in females than in males, for CD4 + T cells, as well as in MBP-and MOG-specific T cells. Likewise, the increase in IL-10-secreting cell numbers after exposure to 1,25-(OH) 2 D 3 was significantly greater in female MS patients for both cell populations (p , 0.0001). These findings were similar in both cultures from MS patients and healthy controls. numbers were measured using flow cytometry. As shown in Fig. 4 
FoxP3
+ T cells showed low or undetectable expression of CD127. No significant differences were observed between MS patients and controls.
Gender influence on vitamin D 3 metabolism
To further investigate the sex-based disparity in immunological effects, vitamin D 3 metabolism was analyzed in males and females. VDR expression has been described in monocytes and activated lymphocytes (31, 32) . Therefore, we chose to examine VDR expression, using quantitative PCR, on MBP-and MOGspecific TCLs isolated from male and female MS patients. As reported previously, resting MBP and MOG peptide-specific TCLs expressed low levels of VDR mRNA, which increased 5-10-fold after activation (p , 0.0001; Fig. 5A ). Moreover, 1,25-(OH) 2 D 3 treatment caused a significant increase in VDR expression (3-7-fold; p , 0.001) in resting and activated MBP and MOG peptidespecific TCLs (Fig. 5A) . Under all conditions studied, male and female patients expressed similar levels of VDR mRNA.
Tissue availability of active vitamin D 3 metabolite 1,25-(OH) 2 D 3 is dependent on the expression of the activating enzyme 1-(OH)ase, and its catabolic counterpart 24-(OH)ase (33, 34) . These enzymes were recently found in different tissues (22, 33) . Therefore, we studied the expression and regulation of CYP27B1 and CYP24A1 transcripts in MBP and MOG peptide-specific T cells. The CYP27B1 gene encodes the enzyme 1-(OH)ase, whereas the CYP24A1 gene encodes the enzyme 24-(OH)ase. As shown in Fig. 5B , resting autoreactive T cells constitutively expressed CYP27B1 mRNA. Levels of expression were significantly upregulated following activation but were not induced further by 1,25-(OH) 2 D 3 nor did transcript expression vary significantly with gender. Male and female patients constitutively expressed similar amounts of T cell CYP27B1 transcripts. In contrast, exposure to 1,25-(OH) 2 D 3 significantly increased CYP24A1 transcripts in self-reactive T cells from males but not females (Fig. 5C ). Interestingly, activation of self-reactive T cells from females inhibited CYP24A1 gene induction (Fig. 5C) . Overall, these data suggest that T cells from males and females synthesize 1,25-(OH) 2 D 3 at similar rates, but females inactivate it more slowly, favoring accumulation in self-reactive T cells. Similar results were obtained using CD4 + T cells specific for tetanus toxoid, streptolysin O, influenza hemagglutinin 307-319 peptide, and polyclonally stimulated T cells. No significant differences were observed between MS patients and healthy controls.
DBP is a serum glycoprotein, synthesized predominantly in the liver, which reversibly binds and transports vitamin D 3 and its metabolites to target cells. Numerous studies detected DBP bound to the surface of several cell types, including human macrophages and lymphocytes, supporting the concept that direct substrate trafficking is pivotal in vitamin D 3 regulation (35) (36) (37) . Therefore, we studied DBP uptake in CD4 + T cells and macrophages isolated from male and female MS patients. As illustrated in Fig. 6A , females and males showed similar circulating DBP levels (32 6 5.04 mg/dl versus 36 6 5.3 mg/dl). In the next experiments, we examined whether DBP uptake differed in males and females. DBP binding and internalization to ex vivo CD4 + T cells, MBP peptide-reactive T cells, and macrophages was a time-dependent function requiring cell activation. Amounts of DBP bound and internalized by resting cells were low; they increased progressively after stimulation, attained peak values at 48-72 h, and decreased thereafter (Fig. 6B-D) . Cells isolated from male and female MS patients followed similar time-dependent profiles. However, the amount of DBP associated with activated cells from female MS patients was 2-5-fold greater than from males with MS ( Fig. 6B-D; p , 0.0001). This effect was similar in cultures from MS patients and healthy controls.
Estrogens modulate vitamin D 3 metabolism
We next investigated possible E2-mediated inhibition of CYP24A1 transcripts and enhancement of DBP uptake. Resting and activated MBP-specific T cells and macrophages from male MS patients were cultured for 72 h, with and without E2, before assessing CYP24A1 transcripts and DBP uptake. Treatment with E2 significantly reduced CYP24A1 transcripts in resting and activated T cells from males ( Fig. 7A ; p , 0.001), and it significantly enhanced DBP uptake in CD4 + T cells and macrophages ( Fig. 7B,  7C ; p , 0.001). Progesterone had no effect on CYP24A1 transcript suppression or DBP uptake enhancement, and the combination of progesterone plus E2 showed similar effects to E2 alone (Fig. 7A-C) . Of note, the estrogen receptor (ER) antagonist ICI 182780 reversed E2 effects on CYP24A1 transcripts and DBP uptake, demonstrating that these effects were ER-signaling dependent (Fig. 7A-C) . To determine the relative contribution of ERa and ERb to E2 effects, male MBP-specific T cells and macrophages were treated with ER-selective ligands. Treatment with propylpyrazole triol, an ERa agonist, reproduced effects observed with E2. In sharp contrast, the ERb agonist diarylpropionitrile had no effect on 1,25-(OH) 2 D 3 metabolism (Fig. 7A-C) .
To establish whether changes in vitamin D 3 metabolism induced by E2 translated into functional changes in autoreactive T cells, we stimulated MBP peptide-specific TCLs from male MS patients with the cognate peptide, in the presence of 1,25-(OH) 2 D 3 plus E2, and examined T cell proliferation, IL-10 secretion, and regulatory T cell induction, as markers of immunosuppressant induction. The addition of E2 to MBP peptide-specific T cells from male MS patients cultured in the presence of 1,25-(OH) 2 D 3 caused a significant increase in the suppression of T cell proliferation ( Fig. 7D ; p , 0.001) Thus, 1,25-(OH) 2 D 3 concentrations required to inhibit 50% of male MBP peptide-specific T cell proliferation in the presence of E2 were similar to those observed in cells isolated from females (Fig. 7D) . Likewise, addition of E2 to male MBP peptide-specific T cells cultured in the presence of 1,25-(OH) 2 D 3 significantly increased the numbers of IL-10-secreting T cells, as well as the induction of CD4 + CD25 + FoxP3 + regulatory T cells ( Fig. 7E, 7F ; p , 0.001). Notably, all of these effects were reversed by the ER antagonist ICI 182780. These results are consistent with the concept that E2 modifies vitamin D 3 metabolism, inducing greater immunosuppressive effects. Results were similar in MS patients and healthy subjects. Because phenol red was reported to exhibit estrogenic effects (28) , it was important to exclude the possibility that it had contributed to or was responsible for E2 effects observed in different immunological responses. A second concern was that culturing of female T cells in vitro depleted their E2 content. Thus, phenol redfree medium was used in parallel cultures with phenol redcontaining medium. Twelve MBP 83-102 TCLs derived from eight MS patients (four females and four males) were selected for these control experiments. Moreover, ex vivo CD4 + T cells isolated from the same group of subjects were also tested in parallel experiments. T cells were evaluated for proliferation, FoxP3 expression, and IL-10 and IFN-g secretion in the presence of increasing concentrations of E2. The data presented as supplemental material indicate that E2 effects were the same whether phenol red was present in the medium. Baseline proliferation, FoxP3 expression, and IL-10 and IFN-g secretion also were not affected by the presence of phenol red. Finally, the addition of ethanol, diluted in the absence of E2 to duplicate ethanol concentrations present at the highest tested dose of E2, had no effect on proliferation, FoxP3 expression, or cytokine secretion (data not shown). Results were similar for MBP [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] TCLs and ex vivo-isolated CD4 + T cells. Overall, the effects observed on proliferation, cytokine secretion, and FoxP3 expression could only be explained by the presence of E2 and not by any other experimental parameter. Although the incidence rates of MS are 2-3-fold greater in women than in men, gender differences in vitamin D 3 metabolism were not evident in the circulation. However, it is still possible that differences in the active metabolite may be evident at local sites of inflammation, as reported in the EAE model, in which vitamin D 3 inhibited severe EAE only in female mice, associated with increased concentrations in the CNS (21) . Indeed, activated myeloid and lymphoid lineage cells upregulate the CYP27B1 gene and local 1,25-(OH) 2 D 3 production for paracrine and intracrine use (33, 38) . Interestingly, ovariectomy abrogates this protective effect (21) , and diestrus-level E2 implants restore vitamin D 3 -mediated EAE resistance in ovariectomized female mice (22) . In this model, the sex-based disparity in EAE susceptibility was associated with CYP24A1 transcript suppression at the spinal cord level, leading to 1,25-(OH) 2 D 3 accumulation, as well as enhancement of VDR gene expression in the CNS of female mice (21) . In our study, just as was observed in the EAE model, activation of self-reactive T cells from females, but not from males, inhibited CYP24A1 gene induction. However, although VDR mRNA was upregulated in self-reactive CD4 + T cells following activation and 1,25-(OH) 2 D 3 exposure, transcript expression did not vary significantly with gender. Discrepancies may be due to differences in the tissues investigated or, alternatively, to differences in vitamin D 3 metabolism between humans and mice.
It is important to note that in these experiments 1,25-(OH) 2 D 3 was used at supraphysiological doses, ∼120-fold greater than circulating levels found in healthy individuals. It seems likely that increasing 1,25(OH) 2 D 3 levels could reduce the risk for MS. If so, it is important to establish optimal vitamin D 3 levels and verify whether vitamin D 3 supplements administered at these levels contribute to prevention without producing side effects. It was suggested that vitamin D 3 should be given at a dose equivalent to 1000-3000 IU daily, to maintain levels at 100 nM/l and, thus, to keep the risk for toxic side effects low (39) . However, confirmation of safety and efficacy in a large randomized trial is needed before general recommendations can be made. Optimal vitamin D 3 supplementation may well be a very individual matter, because there is significant interpersonal variation in response to supplementation. Data from our laboratory obtained in Hispanic individuals suggest that 25-(OH)D 3 levels associated with remission range between 115 and 120 nM, whereas levels associated with relapse are closer to 96-98 nM. These values are distinct from results reported for Finnish individuals: 60 nM during remissions and 44-47 nM during relapses, with no relapses observed for values .85 nM (14) . The discrepancies observed between the Finnish and Hispanic individuals merit further investigation. Moreover, it is important to note that international standards for serum 25-(OH)D 3 have been established from studies of calcium metabolism and bone health and that greater 25-(OH)D 3 concentrations may be required for optimal immune function (40).
Gender differences in MS incidence are not fully understood but might include sex-related differences in immune responsiveness, sex hormone influence, or sex-linked genetic factors (41) . Female mice produce more Abs and show increased cell-mediated immunity after immunization than male mice (42) . Also noteworthy is the fact that women have greater absolute CD4 + lymphocyte counts relative to males, likely contributing to increased immune response (43) . In animal models, transfer of MBP-sensitized lymph node cells into female mice results in severe EAE, whereas transfer into males attenuates disease symptoms (44) . Much attention has been directed toward the actions of sex hormones, such as estrogens, progesterone, and testosterone, during the course of autoimmune diseases, and many findings in humans have been borne out in animal models. For example, administration of E2 confers protection against EAE, collagen-induced arthritis, and adjuvant arthritis in mice and rats (45) (46) (47) . In addition, castration of female mice shortens time to EAE onset (45) . Perhaps the most striking evidence of the modulatory effects of sex hormones on immune function in MS comes from pregnancy. Clinical disease is ameliorated, particularly during the third trimester, when estrogen and progesterone levels are highest, and worsens during the postpartum period, when sex hormone concentrations decrease (48) . Also, following the natural fluctuations in sex hormone levels during the menstrual cycle, MS and rheumatoid arthritis symptoms worsen prior to the onset of menses (49) . However, studies have not been performed to determine how autoimmune responses change longitudinally through the menstrual cycle, as well as during oral contraceptive use or estrogenreplacement therapy. The striking protective effects of E2 on EAE raise the possibility that estrogens might be beneficial in MS. A pilot study reported symptom improvement in postmenopausal MS patients receiving hormone-replacement therapy (50) . Furthermore, in a phase I clinical trial, female MS patients treated with oral estriol showed decreased delayed-type hypersensitivity reactions to tetanus-recall Ags, decreased PBMC IFN-g production, as well as reduced numbers and volumes of gadoliniumenhancing lesions in the brain (51) . The greater incidence of MS in females seems to be contradictory to modulatory effects of estrogens suppressing autoimmunity. However, these discrepancies might be partly reconciled by the fact that estrogens possess biphasic dose effects: lower levels facilitate immune responses, whereas higher ones similar to those present in pregnancy suppress such responses (52) .
Estrogens exert different immunoregulatory effects on the immune system (53) . They inhibit total cell, as well as macrophage and T cell, infiltration into the CNS. This marked reduction in inflammatory cells is reflected in a strong reduction in chemokine and chemokine receptor expression in CNS and lymph node cells (54, 55) . Estrogens also alter macrophage and dendritic cell APC function, blocking Th1 cell activation involved in EAE induction and increased IL-10 secretion (52, 56) . Estrogens increase FoxP3 expression in vivo and in vitro, expanding the regulatory T cell compartment (57), and they reduce IL-12, TNF-a, and IFN-g + T cells, MBP-specific T cells, or macrophages from female and male MS patients were harvested at different times after stimulation with PHA (10 mg/ml), cognate MBP peptide (10 mg/ml), or LPS (5 ng/ml), respectively, and incubated at 4˚C or 37˚C for 60 min in OVA/RPMI 1640 medium containing 2 mM of FITC-DBP. DBP uptake was assessed using flow cytometry. Data represent mean 6 SEM of seven independent experiments conducted in triplicate from samples from different donors.
secretion and strongly enhance IL-10 and TGF-b3 secretion (52, 54, 55, 58) .
In addition to their role in the immune system, estrogens and 1,25-(OH) 2 D 3 have important neuroprotective effects on the CNS. E2 promotes neuron growth and differentiation, acting in concert with different neurotrophins, including brain-derived neurotrophic factor, nerve growth factor, and neurotrophins 3 and 4/5 (59).
These actions promote axon and myelin survival. Likewise, VDRimmunoreactive neurons were described in the hypothalamus and the hippocampus, where 1,25-(OH) 2 D 3 seems to support cell survival (60, 61) . Also, in culture systems, VDR transcripts were detected in astrocytes and oligodendrocytes (62, 63) . These cells respond to 1,25-(OH) 2 D 3 -enhancing transcripts encoding NGF and its low-affinity receptor the p75 protein (63, 64) . Furthermore, 
FoxP3
+ regulatory T cells were measured by flow cytometry. All experiments were conducted in serum-free media. Reagents were dissolved in absolute ethanol at a stock concentration of 0.01 M and further diluted in serum-free medium. The addition of ethanol in concentrations similar to those used for the dilutions of the different reagents did not affect CYP24A1 transcript amounts or DBP uptake. For A, B, C, and E, data represent mean 6 SEM of triplicate cultures from nine independent experiments. For D and F, data represent mean 6 SEM from 25 female and 17 male MS patients. Estrogen action is largely mediated through nuclear hormone receptors. Two ER isoforms have been identified (ERa and ERb), with a selective agonist existing for each (71, 72) . The effects of E2 on 1,25-(OH) 2 D 3 metabolism are reversed by the ER antagonist ICI 182780, suggesting that E2 effects are mediated by ER. By comparing the effects of ER-selective ligands, we found that an ERa-selective agonist reproduced effects observed with E2. In sharp contrast, the ERb agonist showed no effect on 1,25-(OH) 2 D 3 metabolism. This suggests that E2's effects on vitamin D metabolism are mediated primarily through ERa and is consistent with observations indicating that immunomodulatory effects of E2 are dependent on ERa signaling (53, 73) . Expression of both ERs was reported on lymphocytes, and it was recently shown that E2-mediated suppression of certain genes, such as IFN-g and RANTES in the EAE model, is dependent on the presence of ERa (74) . These results are consistent with observations showing treatment of EAE with an ERa-selective ligand reduces CNS inflammation, resulting in delayed onset, as well as decreased incidence and severity of disease. In contrast, little or no effect was observed with ERb-selective ligand, although treatment with ERa or ERb ligands was neuroprotective, as evidenced by the preservation of axons and decreased neuronal abnormalities in gray matter (71, 73) .
Tissue availability of 1,25-(OH) 2 D 3 is dependent on the expression of the activating enzyme 1-(OH)ase and its catabolic counterpart 24-(OH)ase (34) . The activity of these two enzymes is controlled, at least in part, by DBP's affinity for the precursor 25-(OH)D 3 . DBP is a serum glycoprotein that binds and transports vitamin D 3 and its metabolites to target cells (75) . Human DBP has been linked to several membrane components of peripheral blood monocytes, lymphocytes, and neutrophils, supporting the concept of a cell surface-binding site for DBP (35) (36) (37) . In addition, studies demonstrated that in vivo endocytic uptake of the vitamin D 3 -DBP complex is mediated by megalin and cubilin, two members of the low-density lipoprotein-like receptor protein family (76, 77) . However, the mechanism by which vitamin D 3 metabolites dissociate from the internalized complex and travel to specific intracellular destinations is not known. It has been proposed that the hsp-70-related family of intracellular DBPs plays a central role in this transport process (78) . In this study, we demonstrated that amounts of DBP associated with activated cells from female MS patients are 2-5-fold greater than those from males. Furthermore, treatment of male cells with E2 significantly enhanced DBP uptake in CD4 + T cells and macrophages. Interestingly, megalin expression in murine mammary tissue is highest in glands removed during pregnancy and lactation (77) , and supplementation of mice with estrogens and progesterone to stimulate pregnancy enhances megalin expression in ductal mammary epithelial cells (77) . Moreover, studies with megalin knockout mice demonstrated megalin-mediated endocytosis plays a critical role in several tissues, including the thyroid gland and male and female reproductive organs (79, 80) . The impact of E2 on the megalin/cubilin complex and intracellular DBPs, as well as its association with DBP uptake and vitamin D 3 metabolism in self-reactive T cells and macrophages is under investigation in our laboratory.
In summary, the results presented demonstrate a functional synergy between the immunomodulatory effects of 1,25-(OH) 2 D 3 and E2 in MS patients that is mediated by ERa. Gender differences in vitamin D 3 metabolism promoted by estrogens suggest greater protective effects for vitamin D 3 -based therapeutic strategies in women. Conversely, combined deprivation of vitamin D 3 and estrogens, present in menopausal women, could induce significant disease progression in this subgroups of MS patients. Studies relating to these observations should be extended to the mechanistic evaluation of other sexually dimorphic hormones, such as prolactin, and growth hormone. Correction of vitamin D 3 deficiency, in combination with E2, may be useful to suppress autoimmune diseases, such as MS. However, before any conclusions can be drawn, further investigations are needed to determine the optimal doses of both hormones to avoid adverse effects. Likewise, studies are warranted to compare the efficacy and safety of different vitamin D 3 analogs with less hypercalcemic activity, as well as selective ER modulators, such as raloxifene, which has the beneficial properties of estrogens but with a reduced adverse effect profile.
